Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Truist Financial Corp

Truist Financial Corp decreased its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 17.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,167 shares of the company’s stock after selling 862 shares during the quarter. Truist Financial Corp’s holdings in Vaxcyte were worth $341,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PCVX. Janus Henderson Group PLC lifted its holdings in shares of Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after buying an additional 2,052,989 shares during the period. RA Capital Management L.P. lifted its holdings in shares of Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after purchasing an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after purchasing an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Vaxcyte during the third quarter valued at $41,114,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after purchasing an additional 324,560 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Price Performance

PCVX opened at $70.24 on Wednesday. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The business has a 50-day moving average of $83.98 and a 200-day moving average of $94.85. The company has a market capitalization of $9.04 billion, a PE ratio of -15.27 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Guggenheim restated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the completion of the transaction, the chief executive officer now directly owns 136,215 shares in the company, valued at approximately $12,565,833.75. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,616 shares of company stock valued at $5,225,971. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.